Compare HRMY & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | AZTA |
|---|---|---|
| Founded | 2017 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2020 | 1996 |
| Metric | HRMY | AZTA |
|---|---|---|
| Price | $28.56 | $24.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $46.70 | $42.60 |
| AVG Volume (30 Days) | ★ 1.1M | 884.2K |
| Earning Date | 05-18-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.97 | ★ 60.52 |
| EPS | ★ 2.71 | N/A |
| Revenue | ★ $868,453,000.00 | $593,821,000.00 |
| Revenue This Year | $18.83 | $6.25 |
| Revenue Next Year | $12.69 | $5.42 |
| P/E Ratio | $10.70 | ★ N/A |
| Revenue Growth | ★ 21.51 | N/A |
| 52 Week Low | $25.52 | $23.98 |
| 52 Week High | $40.87 | $45.26 |
| Indicator | HRMY | AZTA |
|---|---|---|
| Relative Strength Index (RSI) | 31.12 | 22.46 |
| Support Level | $26.36 | N/A |
| Resistance Level | $37.98 | $32.18 |
| Average True Range (ATR) | 1.89 | 1.27 |
| MACD | -0.55 | -0.26 |
| Stochastic Oscillator | 21.93 | 5.44 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.